Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1957 ARTÍCULOS , VIENDO DEL 211 AL 225

[(18)F]FDG PET outperforms MRI for detecting early tau-related neurodegeneration

Vourkas O, Zhang L, Jimenez-Pérez A, Sánchez-Martín C, Fernández-Álvarez M, Rabano A, Sánchez-Juan P, Silva-Rodríguez J, Grothe MJ; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2026 Oct;53(12):7504-7513. doi: 10.1007/s00259-026-08093-w. Epub 2026 Jul 20.

Omega-3 fatty acids and Alzheimer's disease-related brain biomarkers in older adults enriched for preclinical Alzheimer's disease

Christifano DN, Kelly E, Sands SA, Honea RA, Morris JK, Burns JM, Taylor MK.

Prostaglandins Leukot Essent Fatty Acids. 2026 Oct;210:102762. doi: 10.1016/j.plefa.2026.102762. Epub 2026 Jul 25.

Plasma Biomarkers for Neocortical Tau Burden

Di Molfetta G, Brum WS, Pola I, Tan K, Benedet AL, Sauer M, Montoliu-Gaya L, Janelidze S, Mattsson-Carlgren N, Rahmouni N, Chan T, Denkinger MN, Proitsi P, Zetterberg H, Hansson O, Rosa-Neto P, Ashton NJ.

JAMA Neurol. 2026 Oct 1;83(10):990-1001. doi: 10.1001/jamaneurol.2026.2650.

Development and validation of an amyloid PET dementia of the Alzheimer's type (DAT) score

Edema M, Popuri K, Lee H, Wang L, Beg MF; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2026 Oct;113(3):1263-1276. doi: 10.1177/13872877261476273. Epub 2026 Aug 13.

Rapid plaque clearance with anti-amyloid therapy for Alzheimer's disease: in consideration of donanemab treatment duration from real-world cases

Hwang J, Pietras A, Naasan G, Elahi FM, Gandy S.

Neurocase. 2026 Oct;32(5):229-232. doi: 10.1080/13554794.2026.2730462. Epub 2026 Sep 8.

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders

Teunissen CE, Vermunt L, Barthélemy NR, Benzinger TLS, Graff-Radford J, Verberk IMW, Zetterberg H, Schindler SE, Jack CR Jr.

Lancet Neurol. 2026 Oct;25(10):926-938. doi: 10.1016/S1474-4422(26)00246-2.

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy

Benzinger TLS, Cogswell PM, Arani A, Chaney AM, Hutson K, Glasser MF, Graff-Radford J, McConathy J, Raji CA, Teunissen C, Vemuri P, Zaharchuk G, Jack CR Jr.

Lancet Neurol. 2026 Oct;25(10):939-951. doi: 10.1016/S1474-4422(26)00285-1.

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change

Graff-Radford J, Karliner L, Barnes DE, Frisoni GB, Sperling R, Villain N, Benzinger TLS, Teunissen C, Jack CR Jr.

Lancet Neurol. 2026 Oct;25(10):952-964. doi: 10.1016/S1474-4422(26)00248-6.

The complexities of diagnosing young-onset Alzheimer's dementia and the need for swift identification

Schild AK, Bartels C, Dodel R.

Expert Rev Neurother. 2026 Oct;26(10):923-941. doi: 10.1080/14737175.2026.2733193. Epub 2026 Sep 23.

Blood-based biomarkers in the anti-amyloid era of Alzheimer's disease: clinical utility, implementation challenges, and future directions

Ho BL, Yang YH.

Neurodegener Dis Manag. 2026 Sep 26:1-17. doi: 10.1080/17582024.2026.2734618. Online ahead of print.

Tau-PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head-to-head comparison of Flortaucipir and MK6240

Bizzi I, Macedo AC, Trudel L, Therriault J, Rahmouni N, Lussier FZ, Tissot C, Bezgin G, Aumont É, Chan T, Hosseini SA, Oliva-Lopez D, Gonçalves MP, Povala G, Ferreira PCL, Bellaver B, Amaral L, Ruppert E, Medeiros MS, Mroué R, Rocha A, Ng KP, Zimmer ER, Masdeu J, Pascual B, Lowe VJ, Oh H, Soleimani-Meigooni DN, Fortea J, Ismail Z, Baker S, Pascoal TA, Rosa-Neto P; HEAD Study.

Alzheimers Dement. 2026 Oct;22(10):e71861. doi: 10.1002/alz.71861.

Integrative prediction of Alzheimer's disease and related dementias using multi-omics aging clocks and genetic data

Mostafaei S, Gustavsson K, Hagelin H, Mak JKL, Vu TN, Karlsson IK, Hägg S.

Alzheimers Dement. 2026 Oct;22(10):e71869. doi: 10.1002/alz.71869.

Resting-state functional and spectral alterations underlying cognitive decline in biomarker-confirmed Alzheimer's disease: A systematic review

Alfonsín S, Chino B, de Frutos Lucas J, Delgado-Losada ML, Ojeda N, Maestú F.

Neuroimage Clin. 2026 Sep 27;52:104070. doi: 10.1016/j.nicl.2026.104070. Online ahead of print.

Microglia-derived extracellular vesicle content as a biomarker for early detection of Alzheimer's disease

Woudstra AL, Holtman L, van Vliet EA.

Transl Neurodegener. 2026 Sep 30;15(1):51. doi: 10.1186/s40035-026-00587-9.

Non-invasive neuromodulation in Alzheimer's disease: toward brain-heart coupling as a candidate framework for biomarker-guided adaptive intervention

Zheng W, Ma Y, Su C, Qiu Z, Yan Z, Xu G, Geng D, Wang A.

Rev Neurosci. 2026 Oct 2. doi: 10.1515/revneuro-2026-0134. Online ahead of print.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias